PLx Pharma Inc. Common Stock
PLXP
PLXP was delisted on the 12th of April, 2023.
48 hedge funds and large institutions have $19.3M invested in PLx Pharma Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 18 reducing their positions, and 5 closing their positions.
29% more call options, than puts
Call options by funds: $439K | Put options by funds: $339K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 50 → 48 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
45% less capital invested
Capital invested by funds: $35.4M → $19.3M (-$16.1M)
50% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$112K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$77.7K |
| 3 |
SRC
Shufro Rose & Co
New York
|
+$64.7K |
| 4 |
OQS
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
|
+$51.4K |
| 5 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
+$49.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$510K |
| 2 |
Two Sigma Investments
New York
|
-$455K |
| 3 |
SC
Shay Capital
New York
|
-$358K |
| 4 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
-$350K |
| 5 |
Two Sigma Advisers
New York
|
-$286K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Bank of New York Mellon
New York
| – | -$43K | -10,615 | Closed |
|
PLXP Hedge Fund Activity: Q2 2022 in Review
48 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in PLx Pharma Inc. Common Stock (PLXP) for Q2 2022, worth a combined $19.3M — down 45% from $35.4M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of PLXP and 3 opened new positions — a net loss of 2 holders — while 18 trimmed existing stakes and 9 added.
The largest buyer was Marshall Wace, opening a new position worth an estimated $112K. The largest seller was Morgan Stanley, cutting an estimated $510K.
- 48 institutional investors held PLx Pharma Inc. Common Stock (PLXP) as of Q2 2022, down from 50 in Q1 2022.
- Funds reported $19.3M of PLx Pharma Inc. Common Stock stock for Q2 2022, down 45% quarter-over-quarter.
- 3 funds opened new PLx Pharma Inc. Common Stock positions in Q2 2022 and 5 closed out, a net change of -2 holders.
- The largest PLx Pharma Inc. Common Stock buyer in Q2 2022 was Marshall Wace, an estimated $112K added.
- The largest PLx Pharma Inc. Common Stock seller in Q2 2022 was Morgan Stanley, an estimated $510K sold.
Based on aggregated 13F filings for Q2 2022.